Pharmasset shares jump on IIb hep C data; Feds approve first-in-human stem cell trial;

 @FierceBiotech: Lasers used for painless injections. Report | Follow @FierceBiotech

 @JohnCFierce: For a 2012 insomnia drug, I suspect you'd need more than a placebo comparison to compete in the market. | Follow @JohnCFierce

> Shares of Pharmasset jumped yesterday after the developer reported promising data from a mid-stage trial of its hepatitis C therapy. "We believe the safety, efficacy and resistance profiles revealed today are very encouraging, and that RG7128 is now a further, de-risked program," said Wedbush analyst Y. Katherine Xu. Story

> The FDA has approved the first clinical trial of a human neural stem cell therapy for an aggressive form of brain cancer. Report

> Norway's PCI Biotech has raised $13.74 million through a new rights issue. "The capital increase of NOK 90 millions will enable us to complete the planned clinical development for 3 to 4 selected cancer indications," said CEO Per Walday. When you take into account this strengthened cash position and the very promising results achieved so far in the ongoing Phase I/II study at University College Hospital in London, we are now well positioned for the further development of both our pipeline and PCI Biotech as a company." Release

And Finally... Developers looking for new clues to what triggers autism should check out the results of a new study that links certain genetic mutations to individuals who suffer from the disease. Story

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.